Group 1: Company Overview and AI Medical Layout - Guangzhou Wanfu Biological Technology Co., Ltd. has been investing in AI medical since 2018, aiming to become a leading enterprise in the domestic AI medical field through a "merger + hospital end + consumer end" strategy [2][4] - The company’s investment in Saiweisen Medical Technology led to the first domestic Class III medical device registration for cervical cancer cell digital pathology software in February 2025 [2][3] - Wanfu has developed the "Wanfu Smart Inspection" AI platform for hospitals, which has been implemented in various medical scenarios [3][4] Group 2: Investment and Collaboration - The company collaborates with Saiweisen, Shengqiang, and Yizhun Intelligent to enhance diagnostic capabilities through software and hardware integration [4][5] - The partnership aims to leverage each company's strengths in imaging, pathology, and laboratory testing to capture opportunities in AI applications [4][5] Group 3: Product Development and Market Position - Saiweisen has received the first Class III certification for AI-assisted diagnosis in gynecology, with ongoing clinical trials for non-gynecological applications [5][6] - Shengqiang Technology has developed a comprehensive digital pathology solution, covering approximately 2,000 hospitals domestically and 12 overseas regions [7][8] - Yizhun Intelligent holds 15 Class II and 6 Class III certifications, with a focus on ultrasound AI technology, which is more complex than radiology AI [9][10] Group 4: Market Trends and Future Outlook - The introduction of new policies is expected to significantly increase the volume of digital slices in the pathology market, creating substantial market capacity [8][9] - The AI medical sector is projected to grow rapidly, with a focus on enhancing brand influence and operational efficiency through innovative AI applications [10][11] - The company anticipates a recovery in domestic business in 2026, supported by overseas growth driven by various platforms [12][13]

宁波卡倍亿电气技术股份有限公司 投资者关系活动记录表 证券代码： 300863 证券简称：卡倍亿 6.请介绍一下公司与矩阵超智的合作？ 答：投资者您好！公司墨西哥生产基地已进入产能爬坡阶段，目 前正按计划推进生产经营工作，经营状况良好。公司也曾于 2025 年 3 月 28 日发布公告，公司的墨西哥子公司收到了某国际知名 汽车线束公司的采购定点通知。公司的墨西哥子公司作为该客户 的合格供应商，将为该客户的墨西哥工厂提供汽车用线缆产品, 定点项目具体情况:供货产品为汽车用线缆产品，供货周期为 2025 年至 2027 年，合计供货数量约 164 万公里，预计销售总额 折合人民币约 10 亿元。此外，墨西哥子公司也在与安波福、矢 崎等传统大客户洽谈合作，相关业务进展顺利。 答：投资者您好！公司与上海矩阵超智系统集成有限公司（简称 "矩阵超智"）已正式签署战略合作协议，双方将围绕技术创新、 供应链协同与产业共建等方面展开深度合作，共同推进人形机器 人业务的快速发展。根据战略合作协议，双方将建立长期、稳定 的战略合作伙伴关系。卡倍亿的目标是成为矩阵超智在机器人线 | 缆等领域的重要供应商。双方将通过技术协同、联合开发 ...

Group 1: International Market Performance - The company's overseas revenue growth is attributed to both the expansion of existing international clients (e.g., Budweiser, Carlsberg) and the successful acquisition of new regional customers [2] - Export markets include Southeast Asia, Central and South America, Japan, South Korea, and Africa, with a focus on both existing and new clients [2] - The competitive advantages in East Asia and Southeast Asia are product quality stability, short transportation distances, and quick response to customer needs [2] Group 2: Core Customer Retention - The key advantages for long-term binding with core customers include comprehensive supply chain reliability, production scale, and product quality stability [2] - The company has five production bases across major regions in China, ensuring timely responses to key customer demands [2] - Over 30 years of production experience supports the stability of product taste and quality, which is crucial for maintaining customer trust [2] Group 3: Profit Margin Outlook - The management anticipates improvements in gross margin through enhanced procurement coordination and cost control measures [3] - Gross margin fluctuations are influenced by changes in raw material prices and product pricing, which affect overall revenue [3] - The company aims to solidify its development foundation through product structure upgrades and cost-saving initiatives [3] Group 4: Growth Strategy and Mergers - The company is focused on becoming a world-class malt supplier, with plans for both organic growth and potential mergers or acquisitions [3] - Recent projects have increased production capacity by 27%, with ongoing efforts to optimize capacity based on customer needs [3] - The company seeks to leverage industry opportunities to identify new profit growth points and enhance its business model [3] Group 5: Dividend Policy - The dividend payout ratio is set to increase significantly to over 50% in 2024, indicating a commitment to shareholder returns [3] - Cash dividends distributed in 2022, 2023, and projected for 2024 are 30.39 million, 52.68 million, and 151 million respectively, reflecting a steady increase in payout ratios [3] - The company emphasizes a stable profit distribution policy while balancing capital expenditures and strategic reserves [3]

证券代码：300004 证券简称：南风股份 南方风机股份有限公司投资者关系活动记录表 编号：20260119 | | 特定对象调研 □分析师会议 ☑ | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | 现场参观 ☑ | | | □其他 | | | 华泰证券 田莫充 春晖基金 冯伟贤、黄梓俊 | | | 天风证券 任 康 宝新投资 乐梦琦、舒 玙 | | | 招商证券 朱艺晴 宏惟创世 张玮、谢廷兰 | | 参与单位名称及 | 甬兴证券 凌展翔 中盛晨嘉基金 王方略 | | 人员姓名 | 国联民生 周晓萌 申万研究所 傅浩玮 | | | 南方基金 于泽群 财沣投资 吕 喆 | | | 坤酉基金 冷 波 和君资本 王明贵 | | 时间 | 年 月 日 2026 01 19 | | 地点 | 南方风机股份有限公司 | | 上市公司接待人 | 董事会秘书：王娜女士 | | 员姓名 | 南方增材总经理：卢迪先生 | | | 董事会秘书王娜女士简要介绍了公司的基本情况和业务特 | | | 点，以及公司近期的经营情况。 | | | 投资者 ...

Group 1: Investor Relations Activities - The company conducted multiple investor relations activities from January 5 to January 16, 2026, including phone conferences, on-site research, and strategy meetings with various investment firms [2][3][4][5][6][8] - A total of 39 participants attended the strategy meeting on January 7, while 51 participants joined the strategy meeting on January 13 [3][4] Group 2: Product and Business Development - The company has expanded its product line from frequency converters to servo systems and electric control systems for new energy vehicles, driven by core technology and customer demand [4][5] - The company aims to provide comprehensive solutions by integrating various products, including robotics, vision products, sensors, and precision machinery, to enhance production efficiency and safety [4] Group 3: Focus on Process Industry - The company has made significant progress in the process industry, which is expected to be a key growth area, focusing on reliability and system solutions [4][5] - The company plans to launch a large PLC product for continuous production applications by 2025, addressing the trend of localization in the process industry [4] Group 4: Internationalization Strategy - The company aims to increase the proportion of its overseas business, focusing on brand building and establishing international platforms for sales, R&D, and supply chain [5][6] - The strategy includes exporting customized solutions to multinational clients based on the company's experience in the Chinese market [6] Group 5: Developments in Humanoid Robotics - The company is actively researching humanoid robotics, with plans to develop key components such as bionic arms and actuators by 2025 [7] - The focus will be on providing scene-based products and solutions tailored to customer needs in the manufacturing sector [7] Group 6: Response to Raw Material Price Increases - The company has raised prices on certain products starting January 8, 2026, due to increased production costs from rising prices of chips and raw materials [8] - Continuous product iteration and optimization are being implemented to maintain quality and reduce costs despite market pressures [8]

Group 1: Company Overview and Strategy - The company focuses on enhancing operational efficiency through AI and digital tools to manage sales costs and optimize core processes [2][3] - The company aims to strengthen its core competitive advantage by investing in products with technical barriers and market competitiveness, thereby improving pricing power and sales volume [3][4] - The traditional consumer business serves as a stable cash flow source, supporting the development of new business ventures [3][4] Group 2: Market Expansion and Product Development - The company is expanding into the robotics sector based on its self-developed nano-fluid materials, which have unique properties suitable for enhancing robot components [3][4] - Future growth drivers include leveraging online cross-border channels and deepening collaboration with industrial clients to optimize customer structure [3][4] - The company is actively exploring applications of its materials in commercial aerospace, focusing on differentiated competitive advantages in specific segments [3][4] Group 3: Investment and Acquisition Strategy - Future investments will focus on strengthening the production and sales supply chain, enhancing cross-border sales networks, and optimizing production delivery processes [4] - The strategic positioning is to become a technology-driven platform materials company, emphasizing B2B expansion while maintaining synergy with B2C operations [4]

证券代码：301622 股票简称：英思特 包头市英思特稀磁新材料股份有限公司 投资者关系活动记录表 | | 期回访、问卷调查等方式，了解投资者的需求和意见，不断优 | | | --- | --- | --- | | | 化投资者关系管理工作，以赢得投资者的信任和支持。 | | | 附件清单（如有） | 无 | | | 日期 | 2026 年 01 月 日 | 19 | 切关注市场动态和政策变化，及时预测原材料价格走势，根据 市场需求和原材料价格波动情况，合理调整库存水平。公司通 过根据在手订单提前储备稀土原材料，通过与客户建立调价机 制、优化配方与产品设计、改进工艺等措施，以减少稀土原材 料价格波动对公司经营业绩的不利影响。 采购模式上，公司采用"以产定购+需求预测"的采购模 式。公司会根据客户订单量结合现有库存量统一采购，并会基 于历史数据预测，维持必要的安全库存。同时，公司还注重与 供应商的沟通协作，共同积极应对市场变化和挑战，实现互利 共赢。 4、问：公司未来的市场布局？ 答：公司将持续深耕消费电子领域，坚持高端化、高附加 值的产品定位，通过技术创新与全球产能布局，不断拓展与重 要客户合作的深度和广度。 ...

Group 1: Business Performance and Growth - The company's core products continue to drive growth, with the vaccine business accounting for over 50% of the overall business, becoming a key driver for product structure upgrade [2] - In 2025, the company achieved significant progress in R&D, obtaining the world's first clinical approval for an mRNA vaccine for food animals, and established a GMP mRNA vaccine production line [2] - The company has optimized internal management, resulting in a net profit growth rate significantly higher than revenue growth, showcasing operational resilience [2] Group 2: Market Expansion and Future Plans - In 2025, the company completed multiple overseas product registrations, laying the foundation for future large-scale exports [3] - Future global expansion will focus on new product registrations, acquisitions of overseas companies, and increased R&D investment to gradually enhance the export share of formulations and vaccines [3] - The company aims to deepen its market presence in the pet sector and synthetic biology, contributing to performance growth [2] Group 3: Supply Chain and Coverage - As of 2025, the company's supply chain covers approximately 7,000 pet hospitals and 4,000 pet stores, achieving a national coverage rate of about 35% [3] - Key provinces for supply chain expansion include Guangdong, Jiangsu, and Shandong, while regions like Sichuan and Fujian present untapped market opportunities [3] Group 4: Product Focus and Cost Management - The raw material drug segment will focus on high-margin products such as enrofloxacin and tobramycin, while enhancing production efficiency and reducing unit costs [3] - The company is monitoring the impact of the declining pig cycle on its livestock formulation business, maintaining profitability through comprehensive solutions for poultry clients [4] Group 5: Synthetic Biology Project - The synthetic biology project, initiated in 2025 with a total investment of 680 million yuan, aims to establish a demonstration project for the industrialization of microbial protein [3] - The project is on track, with equipment commissioning and trial production expected to commence by the end of 2026 [3]

证券代码：300689 证券简称：澄天伟业 编号：2026-001 | ☑ 投资者关系活 | 特定对象调研 分析师会议 □ | | --- | --- | | □ 动类别 | 媒体采访 业绩说明会 □ | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 □ 其他 | | 参与单位名称 | 中信证券 | | /人员姓名 | | | 时间 2026 | 年 1 月 19 日 | | 地点 | 深圳市南山区粤海街道高新区社区高新南九道 号深圳湾科技生态 10 | | 园 10 | 栋 B 座 34 楼公司会议室 | | 上市公司接待 | 董事：宋嘉斌 董事会秘书、财务总监：蒋伟红 | | 人员姓名 | | | | 证券事务代表：陈远紫 | | | 一、公司介绍公司基本情况和发展历程。 | | | 二、与调研机构的互动交流。 | | | 公司与调研机构方互动交流的主要内容如下： | | | Q1、公司液冷产品目前向台湾厂商提供的具体有哪些？ | | | 答：公司液冷业务目前已形成多款产品序列。主要提供不锈钢波纹管 | | | 及配套组件，目前也已为台湾客户提供液冷板相关部件，并协助其进 | | 投资者 ...

Group 1: Company Overview and Industry Position - The company’s subsidiary, Fengxing Online, is positioned as a digital entertainment creation and distribution platform, leveraging a leading distribution network with over 400,000 influencers on Douyin and Kuaishou, establishing a significant competitive advantage [1][2]. - Fengxing Online has created an end-to-end commercial closed loop, integrating the "creation-distribution-consumption" process, making it one of the few AI application entities capable of achieving commercialization in the market [2]. Group 2: Content Creation and Distribution - The platform has attracted 15,000 creators, achieving over 2,000 daily active users and accumulating more than 10,000 scripts, thus fostering a diverse content supply ecosystem [2]. - Key business areas include short-to-long and long-to-short adaptations, AI comics, and AI novels, with the first two leading the industry. Several works have achieved over 10 million exposures through the distribution network, becoming new growth engines [2]. Group 3: Technological Advancements - The Orange Star Dream Factory utilizes eight intelligent collaborative technologies, allowing for rapid content production, with single episodes of comics taking only minutes from conception to completion, significantly enhancing production efficiency [3]. - The system supports creators by managing IP, audio, and material resources, enabling them to focus on creativity rather than operational complexities [3]. Group 4: Strategic Partnerships - Fengxing Online has established a deep collaboration with Alibaba Cloud, focusing on co-research and ecosystem creation based on AI content creation technologies [4]. Group 5: Optical Communication Business Development - The optical communication business is identified as the third growth curve, focusing on vertical integration of the supply chain, technological upgrades, and global market expansion [5][6]. - The company is enhancing its supply chain control and cost competitiveness through vertical integration of optical chips, devices, and modules, with PCB production line investments initiated in late 2025 [5]. Group 6: Global Market Strategy - The company aims to establish partnerships with mainstream clients in the domestic market while expanding into international markets through product validation and long-term collaborations [6]. - The strategy includes leveraging existing relationships with international clients to enhance competitiveness in the global market [6]. Group 7: Smart Terminal Business Strategy - The smart terminal business is undergoing a global upgrade, focusing on localized supply capabilities to ensure delivery efficiency and adapt to changing trade environments [7][8]. - The company plans to replicate its domestic manufacturing experience and supply chain integration capabilities in overseas bases to improve efficiency and cost-effectiveness [8].